AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32572849 — intervention group
Group type: EXPERIMENTAL
Intervention: ePIPAC with oxaliplatin (92 mg/m2)
Number of subjects: 20
Study 32572853 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific surgical plates
Number of subjects: 33
Study 32572853 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical plates
Number of subjects: 33
Study 32573371 — intervention group
Group type: EXPERIMENTAL
Intervention: Good collateral group
Number of subjects: 74
Study 32573371 — intervention group
Group type: COMPARATOR
Intervention: Poor collateral group
Number of subjects: 74
Study 32573497 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (recombinant leptin) for 6 months
Number of subjects: 11
Study 32573497 — intervention group
Group type: COMPARATOR
Intervention: Baseline DNL
Number of subjects: 11
Study 32573764 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 944
Study 32573764 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A + Vitamin E trace
Number of subjects: 944
Study 32573764 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A
Number of subjects: 944
Study 32573764 — intervention group
Group type: COMPARATOR
Intervention: Optical coherence tomography
Number of subjects: 944
Study 32573764 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 944
Study 32573816 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient exercise intervention (2 sessions per week for 8 weeks)
Number of subjects: 21
Study 32573983 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stromal cells (MSC)
Number of subjects: 11
Study 32574023 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 0
Study 32574101 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0
Study 32574101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal non-typeable vaccine
Number of subjects: 0
Study 32574101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 0
Study 32574349 — intervention group
Group type: EXPERIMENTAL
Intervention: AGDAS (ano-scrotal)
Number of subjects: 3705
Study 32574349 — intervention group
Group type: EXPERIMENTAL
Intervention: AGDAF (ano-fourchette)
Number of subjects: 3705
Study 32574349 — intervention group
Group type: EXPERIMENTAL
Intervention: AGDAP (ano-penile)
Number of subjects: 3705
Study 32574349 — intervention group
Group type: EXPERIMENTAL
Intervention: AGDAC (ano-clitoral)
Number of subjects: 3705
Study 32574349 — intervention group
Group type: EXPERIMENTAL
Intervention: AGD body size indices (weight, BMI, body surface area, length)
Number of subjects: 3705
Study 32574517 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotic drugs
Number of subjects: 0
Study 32574599 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel monitoring device
Number of subjects: 0
Study 32574803 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback (NF)
Number of subjects: 68
Study 32575130 — intervention group
Group type: EXPERIMENTAL
Intervention: G-POEM (Gastric Peroral Endoscopic Myotomy)
Number of subjects: 76
Study 32575141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior GDM group (413 women)
Number of subjects: 796
Study 32575141 — intervention group
Group type: COMPARATOR
Intervention: Non-GDM group (383 women)
Number of subjects: 796
Study 32575163 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 695
Study 32576092 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Th17 and Th22 Cells
Number of subjects: 0
Study 32576633 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score (0 to 12 points) based on 6 variables: seizure(s) at presentation, known thrombophilia, oral contraception, duration of symptoms >6 days, worst headache ever, focal neurologic deficit at presentation.
Number of subjects: 359
Study 32576633 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimers >675 μg/L (best cutoff)
Number of subjects: 359
Study 32576633 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimers >500 μg/L
Number of subjects: 359
Study 32576633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical score and D-dimers >500 μg/L
Number of subjects: 359
Study 32577626 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E immunogen
Number of subjects: 0
Study 32577626 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA immunogen
Number of subjects: 0
Study 32577878 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR) with intraoperative monitoring (IOM)
Number of subjects: 146
Study 32577878 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR)
Number of subjects: 146
Study 32577878 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive spasticity program
Number of subjects: 146
Study 32578220 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF therapy
Number of subjects: 275
Study 32578441 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPK1 kinase inhibitor (Nec-1)
Number of subjects: 0
Study 32578441 — intervention group
Group type: COMPARATOR
Intervention: Littermate control mice
Number of subjects: 0
Study 32578481 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to 1-year follow-up
Number of subjects: 214
Study 32578481 — intervention group
Group type: EXPERIMENTAL
Intervention: SAQ-7 improvement
Number of subjects: 214
Study 32578962 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired AKI (CA-AKI)
Number of subjects: 1643
Study 32578962 — intervention group
Group type: COMPARATOR
Intervention: In-hospital AKI
Number of subjects: 1643
Study 32578962 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoconcentration
Number of subjects: 1643
Study 32578962 — intervention group
Group type: COMPARATOR
Intervention: Transglomerular pressure gradient
Number of subjects: 1643
Study 32578962 — intervention group
Group type: COMPARATOR
Intervention: Urinary NGAL ratio concentrations
Number of subjects: 1643
Study 32578964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential bortezomib (BTZ) 1.3 mg/m² intravenously + temozolomide (TMZ) therapy
Number of subjects: 10
Study 32578964 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 32579086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece ventilation
Number of subjects: 22
Study 32579284 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely depressed subtype
Number of subjects: 150
Study 32579284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed depression-mania subtype
Number of subjects: 150
Study 32579284 — intervention group
Group type: COMPARATOR
Intervention: Minimal symptom subtype
Number of subjects: 150
Study 32579284 — intervention group
Group type: COMPARATOR
Intervention: Mania subtype
Number of subjects: 150
Study 32579284 — intervention group
Group type: COMPARATOR
Intervention: Moderately depressed subtype
Number of subjects: 150
Study 32579796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rivipansel (840 mg) in subjects with renal impairment
Number of subjects: 44
Study 32579796 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rivipansel (840 mg) in subjects with normal renal function
Number of subjects: 44
Study 32579796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rivipansel (840 mg) in subjects with moderate hepatic impairment
Number of subjects: 44
Study 32579796 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rivipansel (840 mg) in subjects with normal hepatic function
Number of subjects: 44
Study 32580249 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent surgical and nonsurgical therapies after primary treatment failure
Number of subjects: 1558
Study 32580249 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy
Number of subjects: 1558
Study 32580249 — intervention group
Group type: COMPARATOR
Intervention: First-line adjuvant treatment
Number of subjects: 1558
Study 32580252 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Number of subjects: 6938
Study 32580252 — intervention group
Group type: EXPERIMENTAL
Intervention: Drape
Number of subjects: 6938
Study 32580252 — intervention group
Group type: COMPARATOR
Intervention: Alcohol scrub and iodophor drape
Number of subjects: 6938
Study 32580252 — intervention group
Group type: EXPERIMENTAL
Intervention: One-minute alcohol scrub and drape
Number of subjects: 6938
Study 32580586 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Access (CA) after TAVI
Number of subjects: 1936
Study 32580586 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) after TAVI
Number of subjects: 1936
Study 32580597 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-modified T cells
Number of subjects: 0
Study 32580743 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized lunch menu (GHGE-reduced, nutritionally adequate, and affordable) served for four weeks.
Number of subjects: 0
Study 32580743 — intervention group
Group type: COMPARATOR
Intervention: Baseline lunch menu served for four weeks.
Number of subjects: 0
Study 32580757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia (SUA > 7 mg/dL in males and > 6 mg/dL in females)
Number of subjects: 560
Study 32580757 — intervention group
Group type: COMPARATOR
Intervention: Normouricemia (SUA ≤ 7 mg/dL in males and ≤ 6 mg/dL in females)
Number of subjects: 560
Study 32580982 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero Childhood Cancer Personalised Medicine Program
Number of subjects: 0
Study 32580982 — intervention group
Group type: EXPERIMENTAL
Intervention: Formative Evaluation Feedback Loops
Number of subjects: 0
Study 32580982 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network analysis
Number of subjects: 0
Study 32580982 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel recommendations
Number of subjects: 0
Study 32580982 — intervention group
Group type: EXPERIMENTAL
Intervention: Summative evaluation of the Program
Number of subjects: 0
Study 32580988 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic cardiomyopathy assessment and comprehensive cardiovascular and molecular deep phenotyping including echocardiographic and electrocardiographic assessment, heart rate variability, body composition, mitochondrial oxygen metabolism, macrocirculation and microcirculation, endothelial barrier function, routine immunological, haematological and biochemical tests, serum metabolome and lipidome analyses, microbiome and epigenetic modifications of immune cells.
Number of subjects: 0
Study 32580988 — intervention group
Group type: COMPARATOR
Intervention: Control group of patients with cardiomyopathy without infection and healthy subjects.
Number of subjects: 0
Study 32580987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotics
Number of subjects: 0
Study 32580987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure in the first year of life
Number of subjects: 0
Study 32580987 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of the infant oral and intestinal microbiome
Number of subjects: 0
Study 32580987 — intervention group
Group type: EXPERIMENTAL
Intervention: Compositional overlap between maternal intestinal microbiome, breast milk microbiome, and infant oral and intestinal microbiome
Number of subjects: 0
Study 32581505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 229
Study 32581505 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior-ranibizumab eyes
Number of subjects: 229
Study 32581513 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa enzyme replacement therapy (ERT)
Number of subjects: 560
Study 32581513 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa ERT
Number of subjects: 560
Study 32581744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral GPi and bilateral PPN region deep brain stimulation (DBS) electrodes
Number of subjects: 5
Study 32581767 — intervention group
Group type: EXPERIMENTAL
Intervention: EAHE (Erinacine A-Enriched) mycelia capsules, 5 mg/g, three capsules per day for 49 weeks
Number of subjects: 0
Study 32581767 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules, identical in appearance to EAHE capsules, for 49 weeks
Number of subjects: 0
Study 32581961 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Reading Training (RRT) administered for 13 hours over 9 days
Number of subjects: 0
Study 32581961 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Hemisphere-Specific Stimulation (VHSS) + Action Video Game Training (AVG) administered for 13 hours over 9 days
Number of subjects: 0
Study 32582156 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic Adipose Tissue-Derived Stromal/Stem Cells
Number of subjects: 0
Study 32582156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Number of subjects: 0
Study 32582156 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32582547 — intervention group
Group type: EXPERIMENTAL
Intervention: P10s-PADRE vaccine
Number of subjects: 8
Study 32582585 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 32582585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 0
Study 32582595 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 0
Study 32582595 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32582613 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean Fuel Cooking Programs
Number of subjects: 0
Study 32582613 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32582758 — intervention group
Group type: EXPERIMENTAL
Intervention: S-TRAC trial intervention
Number of subjects: 0
Study 32582758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32582855 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional orientation reconstruction of nanoscale features and biomineral crystal lattice using small-angle x-ray scattering and wide-angle x-ray scattering.
Number of subjects: 0
Study 32583052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days)
Number of subjects: 108
Study 32583052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 108
Study 32583288 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score (considered as continuous variable)
Number of subjects: 1766
Study 32583288 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIA score (considered as continuous variable)
Number of subjects: 1766
Study 32583288 — intervention group
Group type: COMPARATOR
Intervention: CHA2DS2-VASc score (considered as categorical variable)
Number of subjects: 1766
Study 32583288 — intervention group
Group type: COMPARATOR
Intervention: ATRIA score (considered as categorical variable)
Number of subjects: 1766
Study 32583306 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cancer patients
Number of subjects: 10684
Study 32583306 — intervention group
Group type: COMPARATOR
Intervention: Cancer patients (active and history)
Number of subjects: 10684
Study 32583749 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon Angioplasty
Number of subjects: 0
Study 32584051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol self-administration (ivASA)
Number of subjects: 85
Study 32584051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low impulsivity or aggression
Number of subjects: 85
Study 32584051 — intervention group
Group type: EXPERIMENTAL
Intervention: First- or second-wave disinhibited traits
Number of subjects: 85
Study 32584260 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVA 2.0 eHealth lifestyle coaching program in addition to the conventional preventive program.
Number of subjects: 340
Study 32584260 — intervention group
Group type: COMPARATOR
Intervention: Conventional preventive program of the municipality.
Number of subjects: 340
Study 32584598 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-2 and IGFBP7 biomarkers
Number of subjects: 0
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO in the 4th quartile (Q4) on day 1
Number of subjects: 957
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin in the 3rd quartile (Q3) and 4th quartile (Q4) on day 2
Number of subjects: 957
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO in the 4th quartile (Q4) on day 2
Number of subjects: 957
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin in the 4th quartile (Q4) on day 7
Number of subjects: 957
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: All quartiles of MPO on day 7
Number of subjects: 957
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of MPO on day 1
Number of subjects: 957
Study 32585739 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of resistin on day 1
Number of subjects: 957
Study 32586337 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tool 1
Number of subjects: 551
Study 32586337 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tool 2
Number of subjects: 551
Study 32586337 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tool 3
Number of subjects: 551
Study 32586346 — intervention group
Group type: COMPARATOR
Intervention: Active treatment (Pravastatin or Atorvastatin) in PROVE-IT trial
Number of subjects: 0
Study 32586346 — intervention group
Group type: COMPARATOR
Intervention: Active treatment (Losartan) in LIFE trial
Number of subjects: 0
Study 32586346 — intervention group
Group type: COMPARATOR
Intervention: Active treatment in HOPE trial
Number of subjects: 0
Study 32586346 — intervention group
Group type: COMPARATOR
Intervention: Placebo in PROVE-IT trial
Number of subjects: 0
Study 32586346 — intervention group
Group type: COMPARATOR
Intervention: Placebo in LIFE trial
Number of subjects: 0
Study 32586346 — intervention group
Group type: COMPARATOR
Intervention: Placebo in HOPE trial
Number of subjects: 0
Study 32586767 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 15 mg/kg or 1200 mg intravenously every 3 weeks for 16 cycles or until loss of clinical benefit
Number of subjects: 17
Study 32586892 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive use of patient-reported outcome measures during follow-up care
Number of subjects: 223
Study 32586892 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no proactive use of patient-reported outcome measures)
Number of subjects: 223
Study 32586892 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 223
Study 32586908 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and dexamethasone
Number of subjects: 0
Study 32586928 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop-mediated isothermal amplification (LAMP) test
Number of subjects: 260
Study 32586928 — intervention group
Group type: COMPARATOR
Intervention: Negative LAMP test
Number of subjects: 260
Study 32586937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1 mg/kg plus Durvalumab 10 mg/kg
Number of subjects: 64
Study 32586937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1 mg/kg plus Tremelimumab 10 mg/kg
Number of subjects: 64
Study 32586937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab in combination with Durvalumab or Tremelimumab
Number of subjects: 64
Study 32587571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 32587571 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 32587748 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based train-the-trainer mealtime intervention delivered by respite care center volunteers
Number of subjects: 0
Study 32587748 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 32588127 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5625
Study 32588127 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 5625
Study 32588218 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (high intake of parenteral fluids)
Number of subjects: 87
Study 32588218 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (low intake of parenteral fluids)
Number of subjects: 87
Study 32588430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer or sodium zirconium cyclosilicate
Number of subjects: 1849
Study 32588430 — intervention group
Group type: COMPARATOR
Intervention: Potassium binders (calcium polystyrene sulfonate, sodium polystyrene sulfonate)
Number of subjects: 1849
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic diets (KDs)
Number of subjects: 932
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic diets (MAD only)
Number of subjects: 932
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: Classical 4:1 KD
Number of subjects: 932
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: MAD
Number of subjects: 932
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: simplified MAD (sMAD)
Number of subjects: 932
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: MAD plus KetoCal
Number of subjects: 932
Study 32588435 — intervention group
Group type: COMPARATOR
Intervention: MAD alone
Number of subjects: 932
Study 32589156 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive guidance intervention
Number of subjects: 110
Study 32589156 — intervention group
Group type: COMPARATOR
Intervention: Routine pediatric care
Number of subjects: 110
Study 32589310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 30 mg/day for 3 weeks, tapered off over 12 weeks
Number of subjects: 29
Study 32589496 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance of patients with surgical complaints during the COVID-19 outbreak
Number of subjects: 0
Study 32589738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevanimibe (ATR-101) at doses of 125, 250, 500, 750, 1000 mg twice daily for 2 weeks followed by a 2-week placebo washout.
Number of subjects: 10
Study 32589738 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the 2-week washout period.
Number of subjects: 10